Picton Mahoney Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.93M Buy
71,232
+4,179
+6% +$585K 0.07% 243
2025
Q4
$8.23M Buy
67,053
+19,427
+41% +$2.36M 0.06% 243
2025
Q3
$5.29M Buy
47,626
+47,612
+340,086% +$5.41M 0.05% 272
2025
Q2
$2K Hold
14
﹤0.01% 708
2025
Q1
$2K Hold
14
﹤0.01% 684
2024
Q4
$1K Hold
14
﹤0.01% 684
2024
Q3
$1K Buy
+14
New +$1.07K ﹤0.01% 677
2015
Q4
Sell
-2,320
Closed -$228K 317
2015
Q3
$228K Buy
2,320
+370
+19% +$41.1K 0.01% 198
2015
Q2
$228K Buy
+1,950
New +$213K 0.01% 202
2015
Q1
Sell
-243,600
Closed -$23M 310
2014
Q4
$23M Buy
+243,600
New +$25.2M 1.09% 26
2014
Q1
Sell
-697,100
Closed -$52.4M 352
2013
Q4
$52.4M Buy
697,100
+23,800
+4% +$1.66M 3.05% 2
2013
Q3
$42.3M Sell
673,300
-173,100
-20% -$10.3M 2.8% 2
2013
Q2
$43.4M Buy
+846,400
New +$44.1M 3.21% 1

Other funds holding GILD

Picton Mahoney Asset Management's GILD Position: Q1 2026 in Review

Picton Mahoney Asset Management increased its Gilead Sciences (GILD) stake by 6.2% in Q1 2026, buying an estimated $585K and bringing the position to 71,232 shares worth $9.93M. The position accounts for 0.07% of the portfolio, ranked #243.

Picton Mahoney Asset Management first reported a position in GILD in Q2 2013 and has held it in 13 quarters since. The position peaked at $52.4M in Q4 2013. 2,313 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Picton Mahoney Asset Management held 71,232 shares of Gilead Sciences worth $9.93M as of Q1 2026.
  • Picton Mahoney Asset Management bought 4,179 Gilead Sciences shares in Q1 2026, an estimated $585K.
  • Gilead Sciences made up 0.07% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #243 holding.
  • Picton Mahoney Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 13 quarters since.
  • Picton Mahoney Asset Management's Gilead Sciences position peaked at $52.4M in Q4 2013.
  • 2,313 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.